Journal article
Multigene testing of moderate-risk genes: Be mindful of the missense
EL Young, BJ Feng, AW Stark, F Damiola, G Durand, N Forey, TC Francy, A Gammon, WK Kohlmann, KA Kaphingst, S McKay-Chopin, T Nguyen-Dumont, J Oliver, AM Paquette, M Pertesi, N Robinot, JS Rosenthal, M Vallee, C Voegele, JL Hopper Show all
Journal of Medical Genetics | Published : 2016
Abstract
Background Moderate-risk genes have not been extensively studied, and missense substitutions in them are generally returned to patients as variants of uncertain significance lacking clearly defined risk estimates. The fraction of early-onset breast cancer cases carrying moderate-risk genotypes and quantitative methods for flagging variants for further analysis have not been established. Methods We evaluated rare missense substitutions identified from a mutation screen of ATM, CHEK2, MRE11A, RAD50, NBN, RAD51, RINT1, XRCC2 and BARD1 in 1297 cases of early-onset breast cancer and 1121 controls via scores from Align-Grantham Variation Grantham Deviation (GVGD), combined annotation dependent dep..
View full abstractRelated Projects (1)
Grants
Awarded by National Cancer Institute
Funding Acknowledgements
This work was supported by the United States National Institutes of Health (NIH) National Cancer Institute (NCI) grants R01 CA121245 and R01 CA155767, by the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer programme, by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, and the Ministere de l'enseignement superieur, de la recherche, de la science, et de la technologie du Quebec through Genome Quebec. The BCFR is supported by grant UM1 CA164920 from the USA National Cancer Institute.